BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental ...

UK Guidelines > Read summaries of UK clinical guidelines on diseases and specialties such as diabetes, oncology, mental health, respiratory disorders, women's health, cardiology, and more.

BOSTON — Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Travere Therapeutics (TVTX – Research Report), with a price target of $27.00. The company’s shares ...

(Getty Images) Sparsentan consistently lowered urine protein/creatinine ratios in a small heterogenous group of individuals with IgAN. The case series demonstrates the efficacy of sparsentan in ...

BOSTON—Proteinuria dropped nearly 70% over 24 weeks in patients with newly diagnosed immunoglobulin A nephropathy (IgAN) treated with sparsentan, according to an abstract that will be presented at the ...

Note 1: Respondents had the option of reporting up to two ancestries on their Census form, and this is captured by the Ancestry multi response (ANCP) variable used in this table. Therefore, the sum of ...

CHRIST (Deemed to be University) was born out of the educational vision of St Kuriakose Elias Chavara, an educationist and social reformer of the nineteenth century in South India. He founded the ...

Travere Therapeutics is likely to be the first beneficiary of these recommendations, having filed a supplemental New Drug Application (sNDA) for Filspari (sparsentan) for FSGS treatment on March 17, ...